Table 2.

Baseline characteristics of the registry data groups



Nontransplantation

Transplantation

Statistical differences
Characteristic
MDS IMRAW
MDS IBMTR
MDS FHCRC
AML IBMTR
P*
P
P
No. of patients   184   193   67   230     
Age, y, median (range)   49.8 (18-60)   39.4 (18-59)   45.6 (20-60)   41.7 (18-60)   <.0001   <.0001   NS  
Male sex, %   58.2   53.4   59.7   53.5   NS   NS   NS  
FAB subtype, %      <.0001   NS   NA  
RA   51.6   30.57   38.81   NA     
RARS   16.9   2.07   4.48   NA     
RAEB   25.0   28.5   37.31   NA     
RAEB-t   6.5   34.72   17.91   NA     
Unknown   0   4.15   1.49   NA     
IPSS risk group, %      <.0001   <.001   NA  
Low   31.0   9.84   2.99   NA     
Int-1   42.9   53.37   32.84   NA     
Int-2   20.1   17.62   46.27   NA     
High
 
6.0
 
19.17
 
17.91
 
NA
 

 

 

 


Nontransplantation

Transplantation

Statistical differences
Characteristic
MDS IMRAW
MDS IBMTR
MDS FHCRC
AML IBMTR
P*
P
P
No. of patients   184   193   67   230     
Age, y, median (range)   49.8 (18-60)   39.4 (18-59)   45.6 (20-60)   41.7 (18-60)   <.0001   <.0001   NS  
Male sex, %   58.2   53.4   59.7   53.5   NS   NS   NS  
FAB subtype, %      <.0001   NS   NA  
RA   51.6   30.57   38.81   NA     
RARS   16.9   2.07   4.48   NA     
RAEB   25.0   28.5   37.31   NA     
RAEB-t   6.5   34.72   17.91   NA     
Unknown   0   4.15   1.49   NA     
IPSS risk group, %      <.0001   <.001   NA  
Low   31.0   9.84   2.99   NA     
Int-1   42.9   53.37   32.84   NA     
Int-2   20.1   17.62   46.27   NA     
High
 
6.0
 
19.17
 
17.91
 
NA
 

 

 

 

MDS indicates myelodysplastic syndrome; AML, acute myelogenous leukemia; Tx, transplant; FAB, French-American-British Classification of Myelodysplastic Syndrome; RA, refractory anemia; RARS, refractory anemia with ringed sideroblasts; RAEB, refractory anemia with excess blasts; RAEB-t, refractory anemia with excess blasts in transformation; IMRAW, International MDS Risk Assessment Workshop; IBMTR, International Bone Marrow Transplant Registry; FHCRC, Fred Hutchison Cancer Research Center; NS, not significant; and NA, not applicable.

*

Probability of testing MDS IMRAW versus all transplantations.

Probability of testing MDS IBMTR versus MDS FHCRC.

Probability of testing MDS versus AML transplantation.

or Create an Account

Close Modal
Close Modal